【와티비커뮤니티-WATVcommunity】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 스포츠뉴스 : 안구정화 놀이터홍보 놀이터후기공유 피해사례공유

로그인

채팅

글쓰기

[IT뉴스]'Disease X' Fears Boost K-Bio[K-Bio pulse]

온카뱅크관리자

2026-05-22 08:07:34

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="XGFsWVpXDl">
 [Seungkwon Kim, Edaily Reporter] On May 20, South Korean bio and healthcare stocks rallied strongly driven by global Hantavirus fears and expectations for new infectious disease countermeasures. 
 Eyegene led the surge, hitting near the daily upper limit after securing a government mRNA vaccine project. GC Medical Science also spiked over 28%, while surgical robot maker LivsMed gained 11% ahead of its new product launch.
 <figure class="figure_frm origin_fig" contents-hash="ccf3b4281e869e4f88a46bb555fb599ee68506e7b8726e3a2120fdbab960a423" dmcf-pid="1ZpCH871EI" dmcf-ptype="figure">
 <img alt="Eyegene trend on May 20.(Image=Naver Finance)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202605/22/Edaily/20260522080508341xyeu.png" data-org-width="708" dmcf-mid="Y57VehcnET" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202605/22/Edaily/20260522080508341xyeu.png" width="658">
 <figcaption class="txt_caption default_figure">
 Eyegene trend on May 20.(Image=Naver Finance)
 </figcaption>
 </figure>
 Eyegene, Tapped for Gov't Hantavirus mRNA Vaccine
 Eyegene surged 29.8% to close at 2,235won. The jump followed its selection for two KDCA-backed national mRNA vaccine projects for Hantavirus and SFTS, securing 4 billionwon in state funding. Utilizing its proprietary, patent-free "Cap-less" mRNA platform, Eyegene aims to develop a universal Hantavirus vaccine. 
 Backed by its largest shareholder's GMP facility, the company is well positioned for immediate mass production and aims to achieve First in Class status globally amid rising pandemic threats.
 <figure class="figure_frm origin_fig" contents-hash="28019ca15c2484c97bab0e389211b8d21df441e39d0a0b593749af68e5dd8891" dmcf-pid="0pbW3e2uEr" dmcf-ptype="figure">
 <img alt="GC Medical Science trend on May 20.(Image=Naver Finance)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202605/22/Edaily/20260522080509588gskz.png" data-org-width="703" dmcf-mid="G0OdAZhDEv" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202605/22/Edaily/20260522080509588gskz.png" width="658">
 <figcaption class="txt_caption default_figure">
 GC Medical Science trend on May 20.(Image=Naver Finance)
 </figcaption>
 </figure>
 GC Medical Science, Surges on Infection Diagnostics Demand
 GC Medical Science rocketed 28.2% to 6,230won. As a subsidiary of the GC Green Cross Group which commercialized the world's first Hantavirus vaccine GC Medical Science benefited from a sector wide rally fueled by global "Disease X" and Hantavirus fears. 
 Although it does not directly produce a specific Hantavirus test kit, investors heavily priced in the group's strong bio security brand power and anticipated growth in broader diagnostic demands.
 <figure class="figure_frm origin_fig" contents-hash="6686e4c28ef67ae9b8860882bec1308bb5af281eb8ac0672220c3a4d611e5dcd" dmcf-pid="7zVXun8BDk" dmcf-ptype="figure">
 <img alt="LivsMed trend on May 20.(Image=Naver Finance)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202605/22/Edaily/20260522080510800ckdb.png" data-org-width="708" dmcf-mid="HuHkhq5TES" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202605/22/Edaily/20260522080510800ckdb.png" width="658">
 <figcaption class="txt_caption default_figure">
 LivsMed trend on May 20.(Image=Naver Finance)
 </figcaption>
 </figure>
 LivsMed, 1000 IP Milestone and Upcoming 'STARK' Launch
 LivsMed climbed 11.3% to 63,000won, driven by its announcement of surpassing 1,000 intellectual property (IP) cases. With an average remaining patent life of 17 years, the company has secured a robust barrier for its core multi joint technologies. 
 Investor anticipation is also building for the May 26 unveiling of its next-generation laparoscopic surgical robot "STARK™" which is poised to drive mid to long term growth and offset recent seasonal earnings volatility.
 김승권 (peace@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

아이진, 한타바이러스 백신 과제 선정에 '上'…녹십자MS·리브스메드 '들썩'[바이... 톰 애스피널 연내 복귀 무산…스파링 재개 못 해

댓글 총 0개

업체홍보/구인 더보기

놀이터홍보 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기